Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Trial of Trotabresib (BMS-986378), an Oral BET Inhibitor) in Combination With Vinorelbine and Radiation Therapy in HER2+ Breast Cancer Patients With Central Nervous System Metastasis and Leptomeningeal Disease (CA076-1008)

NCT06137651 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT06137651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06137651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Trial of Trotabresib (BMS-986378), an Oral BET Inhibitor) in Combination With Vinorelbine and Radiation Therapy in HER2+ Breast Cancer Patients With Central Nervous System Metastasis and Leptomeningeal Disease (CA076-1008)
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2023
Completion date
March 27, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma, metastatic malignant neoplasm in the brain, metastatic malignant neoplasm in the leptomeninges